Delays in recognition and management of giant cell arteritis: Results from a retrospective audit

Clinical Rheumatology

Volumn 30, Issue 2, 2011, Pages 259-262

  Ezeonyeji, Amara N ^a   Borg, Frances A ^a   Dasgupta, Bhaskar ^a  

^a SOUTHEND UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; CEREBROVASCULAR DISEASE; DISEASE DURATION; FEMALE; GIANT CELL ARTERITIS; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; NEUROOPHTHALMOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SOCIAL STATUS; THERAPY DELAY; VISUAL IMPAIRMENT;

ADRENAL CORTEX HORMONES; AGED; DELAYED DIAGNOSIS; FEMALE; GIANT CELL ARTERITIS; HEADACHE; HUMANS; ISCHEMIA; MALE; RETROSPECTIVE STUDIES;

EID: 79954444486     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-010-1616-y     Document Type: Article

References (17)

1. Borg FA, Salter VL, Dasgupta B (2008) Neuro-ophthalmic complications in giant cell arteritis. Curr Allergy Asthma Rep 8:323-330.
2. Gonzalez-Gay MA, Garcia-Porrua C, Llorca J et al (2000) Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients. Med Baltim 79:283-292.
3. Liozon E, Herrmann F, Ly K et al (2001) Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients. Am J Med 111:211-217. (Pubitemid 32786949)
4. Sandercock PA, Warlow CP, Jones LN, Starkey IR (1989) Predisposing factors for cerebral infarction: the Oxfordshire community stroke project. BMJ 298:75-80. (Pubitemid 19032928)
5. Goodman BW Jr (1979) Temporal arteritis. Am J Med 67:839- 852. (Pubitemid 10218838)
6. Font C, Cid MC, Coll-Vinent B, Lopez-Soto A, Grau JM (1997) Clinical features in patients with permanent visual loss due to biopsy-proven giant cell arteritis. Br J Rheumatol 36:251-254.
7. Danesh-Meyer H, Savino PJ, Gamble GG (2005) Poor prognosis of visual outcome after visual loss from giant cell arteritis. Ophthalmology 112:1098-1103. (Pubitemid 40797468)
8. Smetana GW, Shmerling RH (2002) Does this patient have temporal arteritis? JAMA 287:92-101. (Pubitemid 34251681)
9. Nesher G, Berkun Y, Mates M et al (2004) Risk factors for cranial ischemic complications in giant cell arteritis. Med Baltim 83:114- 122. (Pubitemid 38524628)
10. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (1995) Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333:1581-1587.
11. Hacke W, Kaste M, Bluhmki E et al (2008) Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 359:1317-1329.
12. Dasgupta B, Hassan N, British Society for Rheumatology Guidelines Group (2007) Giant cell arteritis: recent advances and guidelines for management. Clin Exp Rheumatol 25:S62-S65. (Pubitemid 46656604)
13. Dasgupta B, Giant Cell Arteritis Guideline Development Group (2010) Concise guidance: diagnosis and management of giant cell arteritis. Clin Med 10:381-386.
14. Mukhtyar C, Guillevin L, Cid MC et al (2009) EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 68:310-317.
15. Hunder GG, Bloch DA, Michel BA et al (1990) The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 33:1122-1128. (Pubitemid 20273297)
16. Cid MC, Font C, Oristrell J et al (1998) Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis Rheum 41:26-32. (Pubitemid 28041919)
17. Hernandez-Rodriguez J, Segarra M, Vilardell C et al (2003) Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giantcell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism. Circulation 107:2428-2434. (Pubitemid 36605224)